Eli Lilly and Co. has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion, in a move that bolsters Lilly’s push into gene editing for cardiovascular conditions and signals renewed confidence in the sector. The all-cash tender offer values Verve at $10.50 per share upfront. That’s a 113% premium over the company’s 30-day…
The FDA Fast-Tracked GNSC-001 gene therapy targets osteoarthritis at its root
One of the largest unmet needs in modern medicine is the effective treatment of osteoarthritis (OA)—a degenerative joint disease afflicting more than 30 million Americans and costing the healthcare system $459.5 billion in all-cause medical costs, according to a 2020 study in the Archives of Physical Medicine and Rehabilitation. “We see this as one of…